We Are Ananda Pharma

We're focused on the development and commercialisation of
CBD-based Therapies

Our proprietary patent-pending drug candidates are targeting complex, chronic conditions in areas of high unmet medical needs.

View Our latest corporate presentation

Backed By Leading Global Companies

The Opportunity For Cannabinoid Medicines

The Global Anti-Inflammatory Drugs Market Is Projected To Reach $118.4bn By 2027

We’re developing regulatory approved medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure

Visit Investor Hub
The Ananda Pharma Approach

From Research
To Patient Delivery:
Our Process Explained

Research

Identify unmet needs where cannabinoids are shown to have clinical potential by reviewing literature, anecdotal evidence and mechanisms of action.

Development

Optimise the drug candidate and plan the route to in-human studies. Cannabinoids are well understood compounds, considered safe by the World Health Organisation so can be taken directly into Phase II and Phase III trials.

Trials

Conduct clinical trials in a relevant patient population, in partnership with leading researchers.

Delivery

Consult and coordinate with regulators to achieve  marketing authorisations and secure access from healthcare providers.

Our Portfolio

Discover Our Clinical Trials

View Full Portfolio

CATE Trials – Investigating MRX2 & MRX2T for Refractory Epilepsies

Epilepsy
UCL
GOSH
NIHR
NHSE
PHASE
I
A
PHASE
II
A
PHASE
III
A
PHASE
IV
A
The aim of this research is to trial two novel cannabinoid medicines; MRX2 (CBD) and MRX2T (CBD in combination with THC), to determine whether they are effective and safe in a broad range of seizure types and epilepsies in children and adults.
View project

ENDOCAN-1: A Pilot Randomised Controlled Trial of the Efficacy of a CBD Oral Tincture in The Mangement of Endometriosis-Associated Pain

Endo
Endometriosis
Endowarrior
CBD for Endometriosis
Endometriosis Pain
PHASE
I
PHASE
II
PHASE
III
PHASE
IV
ENDOCAN-1 will investigate if a future large scale, UK-wide trial to determine whether a cannabinoid can reduce endometriosis-associated pain is possible. 100 women with pelvic pain due to endometriosis will be randomly assigned to take MRX1 CBD drug candidate or identical placebo for 12 weeks.
View project

ACTiON Study : Chemotherapy Induced Peripheral Neuropathy (CIPN)

CIPN
CBD for CIPN
CBD for Chemotherapy Pain
PHASE
I
PHASE
II
PHASE
III
PHASE
IV
ACTiON is a Phase 2, double blind placebo-controlled crossover randomised clinical trial (‘RCT’) to assess Ananda’s patent-pending MRX1 drug candidate versus placebo in the treatment of CIPN.
View project
View Full Portfolio
Our Approach

Transforming Lives Through Cannabinoid Medicines

We believe that cannabidiol, with its multiple molecular and cellular mechanisms of action has the potential to become a crucial element in the treatment plans for many complex conditions, especially in chronic pain and inflammatory indications.

View all our Assets
The Ananda Pharma Board Of Directors

Professionals With A Personal Investment

Our Board of Directors

Charles Morgan
Chairman

Charles Morgan is a resources and technology venture capitalist who has identified emerging sectors and acquired early stage and strategic positions in a wide range of ventures around the globe.

Read More
Melissa Sturgess
Chief Executive Officer

Melissa Sturgess holds a BSc and an MBA and has more than 20 years of experience as a director of UK and Australian Stock Exchange quoted companies, in the roles of Chair, CEO and non-executive director.

Read More
Stuart Piccaver
Non-Executive Director

Stuart, in his role as CEO of JEPCO, has considerable horticultural experience and direct experience of Cannabis cultivation and has been the driving force for many of the leading agricultural initiatives and successes of JEPCO and its associated companies.

Read More
Jeremy Sturgess-Smith
Finance Director

Jeremy Sturgess-Smith is a finance leader with a proven track record in corporate finance, investor relations, and strategic growth.

Read More
John Treacy
Independent Non-Executive Director

Mr Treacy is an experienced London-based small cap financier who specialises in working with growing companies. He qualified as a solicitor in the London office of a major international law firm where he specialised in Capital Markets and Mergers & Acquisitions.

Read More
Professor Clive Page
Non-Executive Director

Clive Page is a Professor of Pharmacology, King’s College London and Director of The Pulmonary Pharmacology Unit, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory diseases, and he has published over 250 scientific papers.

Read More

You can read more about each of our board members on our board of directors page.

Invest In Our Future Success

Contact UsInvestor Hub